Hipertensão portopulmonar Portopulmonary hypertension
Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1%...
Ausführliche Beschreibung
Autor*in: |
Eduardo Garcia [verfasserIn] José Silva Moreira [verfasserIn] Ajácio Bandeira de Melo Brandão [verfasserIn] Alessandra Isabel Zille [verfasserIn] Juliana Cardozo Fernandes [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch ; Portugiesisch |
Erschienen: |
2005 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Jornal Brasileiro de Pneumologia - Sociedade Brasileira de Pneumologia e Tisiologia, 2005, 31(2005), 2, Seite 157-161 |
---|---|
Übergeordnetes Werk: |
volume:31 ; year:2005 ; number:2 ; pages:157-161 |
Links: |
Link aufrufen |
---|
DOI / URN: |
10.1590/S1806-37132005000200012 |
---|
Katalog-ID: |
DOAJ043625827 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ043625827 | ||
003 | DE-627 | ||
005 | 20230308073147.0 | ||
007 | cr uuu---uuuuu | ||
008 | 230227s2005 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1590/S1806-37132005000200012 |2 doi | |
035 | |a (DE-627)DOAJ043625827 | ||
035 | |a (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng |a por | ||
050 | 0 | |a RC705-779 | |
100 | 0 | |a Eduardo Garcia |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hipertensão portopulmonar Portopulmonary hypertension |
264 | 1 | |c 2005 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. | ||
650 | 4 | |a Hipertensão portopulmonar | |
650 | 4 | |a Cirrose | |
650 | 4 | |a Pressão arterial pulmonar | |
650 | 4 | |a Hipertensão pulmonar | |
650 | 4 | |a Vasodilatadores | |
650 | 4 | |a Oxygen free radicals | |
650 | 4 | |a Antioxidant substances | |
650 | 4 | |a Oxidative stress | |
650 | 4 | |a Lung diseases | |
653 | 0 | |a Diseases of the respiratory system | |
700 | 0 | |a José Silva Moreira |e verfasserin |4 aut | |
700 | 0 | |a Ajácio Bandeira de Melo Brandão |e verfasserin |4 aut | |
700 | 0 | |a Alessandra Isabel Zille |e verfasserin |4 aut | |
700 | 0 | |a Juliana Cardozo Fernandes |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Jornal Brasileiro de Pneumologia |d Sociedade Brasileira de Pneumologia e Tisiologia, 2005 |g 31(2005), 2, Seite 157-161 |w (DE-627)508330513 |w (DE-600)2223157-2 |x 18063756 |7 nnns |
773 | 1 | 8 | |g volume:31 |g year:2005 |g number:2 |g pages:157-161 |
856 | 4 | 0 | |u https://doi.org/10.1590/S1806-37132005000200012 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 |z kostenfrei |
856 | 4 | 0 | |u http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1806-3713 |y Journal toc |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1806-3756 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_31 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 31 |j 2005 |e 2 |h 157-161 |
author_variant |
e g eg j s m jsm a b d m b abdmb a i z aiz j c f jcf |
---|---|
matchkey_str |
article:18063756:2005----::ietnootploaproumnr |
hierarchy_sort_str |
2005 |
callnumber-subject-code |
RC |
publishDate |
2005 |
allfields |
10.1590/S1806-37132005000200012 doi (DE-627)DOAJ043625827 (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 DE-627 ger DE-627 rakwb eng por RC705-779 Eduardo Garcia verfasserin aut Hipertensão portopulmonar Portopulmonary hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases Diseases of the respiratory system José Silva Moreira verfasserin aut Ajácio Bandeira de Melo Brandão verfasserin aut Alessandra Isabel Zille verfasserin aut Juliana Cardozo Fernandes verfasserin aut In Jornal Brasileiro de Pneumologia Sociedade Brasileira de Pneumologia e Tisiologia, 2005 31(2005), 2, Seite 157-161 (DE-627)508330513 (DE-600)2223157-2 18063756 nnns volume:31 year:2005 number:2 pages:157-161 https://doi.org/10.1590/S1806-37132005000200012 kostenfrei https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 kostenfrei https://doaj.org/toc/1806-3713 Journal toc kostenfrei https://doaj.org/toc/1806-3756 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2005 2 157-161 |
spelling |
10.1590/S1806-37132005000200012 doi (DE-627)DOAJ043625827 (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 DE-627 ger DE-627 rakwb eng por RC705-779 Eduardo Garcia verfasserin aut Hipertensão portopulmonar Portopulmonary hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases Diseases of the respiratory system José Silva Moreira verfasserin aut Ajácio Bandeira de Melo Brandão verfasserin aut Alessandra Isabel Zille verfasserin aut Juliana Cardozo Fernandes verfasserin aut In Jornal Brasileiro de Pneumologia Sociedade Brasileira de Pneumologia e Tisiologia, 2005 31(2005), 2, Seite 157-161 (DE-627)508330513 (DE-600)2223157-2 18063756 nnns volume:31 year:2005 number:2 pages:157-161 https://doi.org/10.1590/S1806-37132005000200012 kostenfrei https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 kostenfrei https://doaj.org/toc/1806-3713 Journal toc kostenfrei https://doaj.org/toc/1806-3756 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2005 2 157-161 |
allfields_unstemmed |
10.1590/S1806-37132005000200012 doi (DE-627)DOAJ043625827 (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 DE-627 ger DE-627 rakwb eng por RC705-779 Eduardo Garcia verfasserin aut Hipertensão portopulmonar Portopulmonary hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases Diseases of the respiratory system José Silva Moreira verfasserin aut Ajácio Bandeira de Melo Brandão verfasserin aut Alessandra Isabel Zille verfasserin aut Juliana Cardozo Fernandes verfasserin aut In Jornal Brasileiro de Pneumologia Sociedade Brasileira de Pneumologia e Tisiologia, 2005 31(2005), 2, Seite 157-161 (DE-627)508330513 (DE-600)2223157-2 18063756 nnns volume:31 year:2005 number:2 pages:157-161 https://doi.org/10.1590/S1806-37132005000200012 kostenfrei https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 kostenfrei https://doaj.org/toc/1806-3713 Journal toc kostenfrei https://doaj.org/toc/1806-3756 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2005 2 157-161 |
allfieldsGer |
10.1590/S1806-37132005000200012 doi (DE-627)DOAJ043625827 (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 DE-627 ger DE-627 rakwb eng por RC705-779 Eduardo Garcia verfasserin aut Hipertensão portopulmonar Portopulmonary hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases Diseases of the respiratory system José Silva Moreira verfasserin aut Ajácio Bandeira de Melo Brandão verfasserin aut Alessandra Isabel Zille verfasserin aut Juliana Cardozo Fernandes verfasserin aut In Jornal Brasileiro de Pneumologia Sociedade Brasileira de Pneumologia e Tisiologia, 2005 31(2005), 2, Seite 157-161 (DE-627)508330513 (DE-600)2223157-2 18063756 nnns volume:31 year:2005 number:2 pages:157-161 https://doi.org/10.1590/S1806-37132005000200012 kostenfrei https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 kostenfrei https://doaj.org/toc/1806-3713 Journal toc kostenfrei https://doaj.org/toc/1806-3756 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2005 2 157-161 |
allfieldsSound |
10.1590/S1806-37132005000200012 doi (DE-627)DOAJ043625827 (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 DE-627 ger DE-627 rakwb eng por RC705-779 Eduardo Garcia verfasserin aut Hipertensão portopulmonar Portopulmonary hypertension 2005 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases Diseases of the respiratory system José Silva Moreira verfasserin aut Ajácio Bandeira de Melo Brandão verfasserin aut Alessandra Isabel Zille verfasserin aut Juliana Cardozo Fernandes verfasserin aut In Jornal Brasileiro de Pneumologia Sociedade Brasileira de Pneumologia e Tisiologia, 2005 31(2005), 2, Seite 157-161 (DE-627)508330513 (DE-600)2223157-2 18063756 nnns volume:31 year:2005 number:2 pages:157-161 https://doi.org/10.1590/S1806-37132005000200012 kostenfrei https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 kostenfrei http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 kostenfrei https://doaj.org/toc/1806-3713 Journal toc kostenfrei https://doaj.org/toc/1806-3756 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 31 2005 2 157-161 |
language |
English Portuguese |
source |
In Jornal Brasileiro de Pneumologia 31(2005), 2, Seite 157-161 volume:31 year:2005 number:2 pages:157-161 |
sourceStr |
In Jornal Brasileiro de Pneumologia 31(2005), 2, Seite 157-161 volume:31 year:2005 number:2 pages:157-161 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases Diseases of the respiratory system |
isfreeaccess_bool |
true |
container_title |
Jornal Brasileiro de Pneumologia |
authorswithroles_txt_mv |
Eduardo Garcia @@aut@@ José Silva Moreira @@aut@@ Ajácio Bandeira de Melo Brandão @@aut@@ Alessandra Isabel Zille @@aut@@ Juliana Cardozo Fernandes @@aut@@ |
publishDateDaySort_date |
2005-01-01T00:00:00Z |
hierarchy_top_id |
508330513 |
id |
DOAJ043625827 |
language_de |
englisch portugiesisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043625827</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308073147.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2005 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S1806-37132005000200012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043625827</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Eduardo Garcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hipertensão portopulmonar Portopulmonary hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hipertensão portopulmonar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cirrose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pressão arterial pulmonar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hipertensão pulmonar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vasodilatadores</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxygen free radicals</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antioxidant substances</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxidative stress</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">José Silva Moreira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ajácio Bandeira de Melo Brandão</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandra Isabel Zille</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Juliana Cardozo Fernandes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Jornal Brasileiro de Pneumologia</subfield><subfield code="d">Sociedade Brasileira de Pneumologia e Tisiologia, 2005</subfield><subfield code="g">31(2005), 2, Seite 157-161</subfield><subfield code="w">(DE-627)508330513</subfield><subfield code="w">(DE-600)2223157-2</subfield><subfield code="x">18063756</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:157-161</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S1806-37132005000200012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1806-3713</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1806-3756</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">157-161</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Eduardo Garcia |
spellingShingle |
Eduardo Garcia misc RC705-779 misc Hipertensão portopulmonar misc Cirrose misc Pressão arterial pulmonar misc Hipertensão pulmonar misc Vasodilatadores misc Oxygen free radicals misc Antioxidant substances misc Oxidative stress misc Lung diseases misc Diseases of the respiratory system Hipertensão portopulmonar Portopulmonary hypertension |
authorStr |
Eduardo Garcia |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)508330513 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RC705-779 |
illustrated |
Not Illustrated |
issn |
18063756 |
topic_title |
RC705-779 Hipertensão portopulmonar Portopulmonary hypertension Hipertensão portopulmonar Cirrose Pressão arterial pulmonar Hipertensão pulmonar Vasodilatadores Oxygen free radicals Antioxidant substances Oxidative stress Lung diseases |
topic |
misc RC705-779 misc Hipertensão portopulmonar misc Cirrose misc Pressão arterial pulmonar misc Hipertensão pulmonar misc Vasodilatadores misc Oxygen free radicals misc Antioxidant substances misc Oxidative stress misc Lung diseases misc Diseases of the respiratory system |
topic_unstemmed |
misc RC705-779 misc Hipertensão portopulmonar misc Cirrose misc Pressão arterial pulmonar misc Hipertensão pulmonar misc Vasodilatadores misc Oxygen free radicals misc Antioxidant substances misc Oxidative stress misc Lung diseases misc Diseases of the respiratory system |
topic_browse |
misc RC705-779 misc Hipertensão portopulmonar misc Cirrose misc Pressão arterial pulmonar misc Hipertensão pulmonar misc Vasodilatadores misc Oxygen free radicals misc Antioxidant substances misc Oxidative stress misc Lung diseases misc Diseases of the respiratory system |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Jornal Brasileiro de Pneumologia |
hierarchy_parent_id |
508330513 |
hierarchy_top_title |
Jornal Brasileiro de Pneumologia |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)508330513 (DE-600)2223157-2 |
title |
Hipertensão portopulmonar Portopulmonary hypertension |
ctrlnum |
(DE-627)DOAJ043625827 (DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09 |
title_full |
Hipertensão portopulmonar Portopulmonary hypertension |
author_sort |
Eduardo Garcia |
journal |
Jornal Brasileiro de Pneumologia |
journalStr |
Jornal Brasileiro de Pneumologia |
callnumber-first-code |
R |
lang_code |
eng por |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2005 |
contenttype_str_mv |
txt |
container_start_page |
157 |
author_browse |
Eduardo Garcia José Silva Moreira Ajácio Bandeira de Melo Brandão Alessandra Isabel Zille Juliana Cardozo Fernandes |
container_volume |
31 |
class |
RC705-779 |
format_se |
Elektronische Aufsätze |
author-letter |
Eduardo Garcia |
doi_str_mv |
10.1590/S1806-37132005000200012 |
author2-role |
verfasserin |
title_sort |
hipertensão portopulmonar portopulmonary hypertension |
callnumber |
RC705-779 |
title_auth |
Hipertensão portopulmonar Portopulmonary hypertension |
abstract |
Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. |
abstractGer |
Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. |
abstract_unstemmed |
Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_31 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2014 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
2 |
title_short |
Hipertensão portopulmonar Portopulmonary hypertension |
url |
https://doi.org/10.1590/S1806-37132005000200012 https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09 http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012 https://doaj.org/toc/1806-3713 https://doaj.org/toc/1806-3756 |
remote_bool |
true |
author2 |
José Silva Moreira Ajácio Bandeira de Melo Brandão Alessandra Isabel Zille Juliana Cardozo Fernandes |
author2Str |
José Silva Moreira Ajácio Bandeira de Melo Brandão Alessandra Isabel Zille Juliana Cardozo Fernandes |
ppnlink |
508330513 |
callnumber-subject |
RC - Internal Medicine |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.1590/S1806-37132005000200012 |
callnumber-a |
RC705-779 |
up_date |
2024-07-03T18:34:55.066Z |
_version_ |
1803583954692866048 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ043625827</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230308073147.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230227s2005 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1590/S1806-37132005000200012</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ043625827</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ91834ed5904d44fc88a8a75f95cf4f09</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield><subfield code="a">por</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC705-779</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Eduardo Garcia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Hipertensão portopulmonar Portopulmonary hypertension</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2005</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Hipertensão portal e cirrose podem causar complexas alterações do leito vascular pulmonar, dentre elas a síndrome hepatopulmonar e a hipertensão portopulmonar. A associação de hipertensão pulmonar com cirrose e hipertensão portal é pouco diagnosticada, sendo sua prevalência estimada por volta de 1% a 2% dos pacientes com hipertensão portal ou cirrose, sem preferência por sexo, e com predomínio na faixa dos 40 anos. Fatores etiológicos não foram bem definidos para explicar o aumento da pressão da artéria pulmonar e da resistência vascular pulmonar. A maioria dos pacientes é assintomática até que desenvolva dispnéia aos esforços, o que geralmente ocorre quando a pressão média na artéria pulmonar ultrapassa o valor de 40 mmHg. A mortalidade é elevada pela associação de doença hepática e hipoxemia progressiva ou falência ventricular direita. Novos estudos são necessários para se estabelecer os benefícios do uso dos vasodilatadores orais, inalatórios ou endovenosos e os resultados do transplante hepático, talvez a única possibilidade terapêutica definitiva.<br<Portal hypertension and cirrhosis can result in complex changes in the pulmonary vascular bed, the most important among them being the hepatopulmonary syndrome and portopulmonary hypertension. When pulmonary hypertension accompanies cirrhosis and portal hypertension, it is seldom diagnosed. Its prevalence is estimated to range from 1% to 2% in patients with portal hypertension or cirrhosis, regardless of gender, and the condition is predominantly seen in patients in their 40s. Etiologic factors have not been sufficiently well defined to explain the increase in pulmonary artery pressure and pulmonary vascular resistance. Most patients are asymptomatic until developing dyspnea on exertion, which generally occurs when the mean pulmonary artery pressure exceeds 40 mmHg. Concomitant hepatic disease with progressive hypoxemia or right ventricular failure increase mortality rates. Further studies are needed in order to determine the benefits of using oral, inhaled or intravenous vasodilators, as well as to evaluate the outcomes of liver transplant, which may be the sole definitive therapeutic option.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hipertensão portopulmonar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Cirrose</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Pressão arterial pulmonar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Hipertensão pulmonar</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Vasodilatadores</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxygen free radicals</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Antioxidant substances</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Oxidative stress</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Lung diseases</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the respiratory system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">José Silva Moreira</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Ajácio Bandeira de Melo Brandão</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Alessandra Isabel Zille</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Juliana Cardozo Fernandes</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Jornal Brasileiro de Pneumologia</subfield><subfield code="d">Sociedade Brasileira de Pneumologia e Tisiologia, 2005</subfield><subfield code="g">31(2005), 2, Seite 157-161</subfield><subfield code="w">(DE-627)508330513</subfield><subfield code="w">(DE-600)2223157-2</subfield><subfield code="x">18063756</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:31</subfield><subfield code="g">year:2005</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:157-161</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1590/S1806-37132005000200012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/91834ed5904d44fc88a8a75f95cf4f09</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1806-37132005000200012</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1806-3713</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1806-3756</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_31</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">31</subfield><subfield code="j">2005</subfield><subfield code="e">2</subfield><subfield code="h">157-161</subfield></datafield></record></collection>
|
score |
7.3994474 |